The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Zanubrutinib for R/R primary CNS lymphoma: the initial results of the PRiZM+ platform study
Chris Fox, MBChB(Hons), MRCP, FRCPath, University of Nottingham, Nottingham, UK, outlines the initial results from the PRiZM+ Phase II platform study (ISRCTN90634455) of zanubrutinib in patients with relapsed/refractory (R/R) primary central nervous system (CNS) lymphoma. Dr Fox presents the findings of the zanubrutinib monotherapy cohort and highlights that, despite this being a difficult-to-treat patient population with a short duration of first response, the overall response rate (ORR) was encouraging. The PRiZM+ study will now look at zanubrutinib in combination with other agents. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy/advisory boards: AbbVie, AstraZeneca, Atarabio, BMS, GenMab, Gilead/Kite, Incyte, Janssen, Lilly, Morphosys, Ono, Roche, SERB, SOBI, Takeda; Educational activities: AbbVie, Kite/Gilead, Incyte, Janssen, Roche, Takeda, SERB; Travel: Roche, Kite/Gilead; Research funding: BeiGene, AbbVie/GenMab.
